Talha Badar: ASH23, a few selected MDS abstracts to watch out at this year ASH meeting
Talha Badar, Assistant Professor of Oncology at Mayo Clinic Comprehensive Cancer Center, posted on X/Twitter:
”Weekend review. ASH23, few selected MDS abstracts to watch out at this year ASH meeting.
197: Clinical and Genomic-Based Decision Support System to Define Optimal Timing of Allogeneic Hematopoietic Stem Cell Transplantation in Pts with MDS. Web application for the MDS Transplantation Decision Support System, that allows clinicians to define the best timing for HSCT!
1002: Clinical Implications of TP53 Mutations/Allelic State in Pts with MDS Treated with Hypomethylating Agents (HMA)- a Multicenter, Retrospective Analysis from the Validate Database. TP53 allelic status or type of HMA therapy had no significant impact on outcome.
316: Outcome Prediction in DDX41m MDS Is Not Possible with General Disease Schemes and Requires a Dedicated Risk Scoring System. IPSS-R/M are not able to adequately prognosticate outcome. Truncated variants with DDX41 somatic variants, relatively had inferior outcome.
195: Efficacy and Safety of Roxadustat for Treatment of Anemia in Patients with LR-MDS with Low Red Blood Cell (RBC) Transfusion Burden: Results of Phase III Matterhorn Study. Roxadustat (HIF inhibitor), showed better TI but not statistically significant.
319: Efficacy and Safety of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes. Updated results on 107 pts, ORR (CR,PR,mCR) 86%. mOS 26 mo.
321: Venetoclax Improves Response Rates but Not Survival in CMML Treated with Hypomethylating Agents: A Multicenter, Propensity Score Analysis. Ven in combination with HMA improves response rates but not OS compared to HMA alone.
323: Prognostic Value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes with Intensive Chemotherapy Treatment: Analysis of HOVON-SAKK Studies. Multi-parameter FCM with cut off 0.1%, used for MRD: predictive of OS in high risk MDS, MDS/AML.
322: Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML:
- 23 pts (11 MDS/CMML post HMA/ 12 MRD + AML);
- ORR 64% in MDS/CMML and 25% AML;
- Responses observed regardless of CD123+.
320: Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Higher Risk Myelodysplastic Syndromes (MDS). AZA plus immune based Rx IMM01, ORR 82%, CR 36%. Pt characteristics.”
Source: Talha Badar/Twitter